{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:02Z","timestamp":1789056422501,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Fundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009960","name":"Wellbeing Services County of Pirkanmaa Tays Hospital System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010600","name":"Tays","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201827","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:51:22Z","timestamp":1786737082000},"page":"201827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fragile skin may benefit from decoration"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4027-1759","authenticated-orcid":false,"given":"Tero A.H.","family":"J\u00e4rvinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201827_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(25)00778-0","article-title":"Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial","volume":"406","author":"Tang","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201827_bib2","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201827_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.omta.2026.201737","article-title":"Systemic clinical-grade recombinant decorin reduces disease burden and fibrosis in advanced recessive dystrophic epidermolysis bullosa","volume":"34","author":"Gretzmeier","year":"2026","journal-title":"Mol. Ther. Adv."},{"key":"10.1016\/j.omta.2026.201827_bib4","doi-asserted-by":"crossref","first-page":"21671","DOI":"10.1073\/pnas.1016233107","article-title":"Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice","volume":"107","author":"J\u00e4rvinen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201827_bib5","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1093\/hmg\/ddu102","article-title":"Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-\u03b2 signalling in modifying disease severity","volume":"23","author":"Odorisio","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201827_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.matbio.2022.06.007","article-title":"Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-\u03b2 antagonist and inhibitor of fibrosis","volume":"111","author":"Chac\u00f3n-Solano","year":"2022","journal-title":"Matrix Biol."},{"key":"10.1016\/j.omta.2026.201827_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2026.05.004","article-title":"Engineered natural extracellular matrix platform for modelling skin diseases and identifying therapeutic targets","author":"Malta","year":"2026","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.omta.2026.201827_bib8","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/stem.2907","article-title":"Cord Blood-Derived Stem Cells Suppress Fibrosis and May Prevent Malignant Progression in Recessive Dystrophic Epidermolysis Bullosa","volume":"36","author":"Liao","year":"2018","journal-title":"Stem Cell."},{"key":"10.1016\/j.omta.2026.201827_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.matbio.2018.12.001","article-title":"Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa","volume":"81","author":"Cianfarani","year":"2019","journal-title":"Matrix Biol."},{"key":"10.1016\/j.omta.2026.201827_bib10","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.ymthe.2020.05.017","article-title":"Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa","volume":"28","author":"Pemmari","year":"2020","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600162X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600162X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:14:41Z","timestamp":1789053281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X2600162X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X2600162X"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201827","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fragile skin may benefit from decoration","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201827"}}